Authors: Nir Lubezky Evan Winograd Michael Papoulas Guy Lahat Einat ShachamShmueli Ravit Geva Richard Nakache Joseph Klausner Menahem BenHaim
Publish Date: 2013/01/09
Volume: 17, Issue: 3, Pages: 527-532
Abstract
Bevacizumab has been shown to increase progression free and overall survival in patients with metastatic colorectal cancer Neoadjuvant bevacizumab is commonly used in patients undergoing liver resection Our purpose was to evaluate whether bevacizumab is associated with increased rate of perioperative complications in patients undergoing hepatic resection for colorectal liver metastases CRLMRetrospective analysis of patients undergoing hepatic resection for CRLM who received chemotherapy and bevacizumab group 1 n = 134 or chemotherapy alone group 2 n = 57 We compared demographics surgical characteristics and perioperative coursePerioperative complications developed in 35 of patients in group 1 and 47 in group 2 p = 011 Of those complications 15 112 in group 1 and 5 88 in group 2 were considered major p = 0617 Four patients all of whom received preoperative bevacizumab developed enteric leaks following combined liver and bowel resection The rate of anastomotic leak in group 1 was 10 compared with 0 in group 2 p = 056Neoadjuvant chemotherapy along with bevacizumab was not associated with an increased risk of postoperative complications after hepatic resection Possible association of increased morbidity with simultaneous bowel and liver resections following bevacizumab administration was found and we recommend avoiding such treatment combination
Keywords: